SAB Biotherapeutics Inc (SABS) — Financial Flexibility Index
SAB Biotherapeutics Inc (SABS) has a Financial Flexibility Index of -0.74x as of December 2025. Free cash flow of $-15.84 Million (operating CF $-16.78 Million minus capex $933.15K) represents -1% of total liabilities ($21.32 Million). Check SAB Biotherapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SAB Biotherapeutics Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for SAB Biotherapeutics Inc across 7 annual periods. See how liquid is SAB Biotherapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for SAB Biotherapeutics Inc (2019–2025)
Year-by-year free cash flow to debt coverage for SAB Biotherapeutics Inc. For the full company profile including market capitalisation, see market value of SAB Biotherapeutics Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.06x | $-43.84 Million | $-44.78 Million | $21.32 Million | ▼ -10.4% |
| 2024 | -1.86x | $-33.95 Million | $-34.29 Million | $18.23 Million | ▼ -99.2% |
| 2023 | -0.94x | $-24.92 Million | $-25.12 Million | $26.64 Million | ▲ +12.8% |
| 2022 | -1.07x | $-21.29 Million | $-23.46 Million | $19.85 Million | ▼ -453.4% |
| 2021 | 0.30x | $12.93 Million | $1.99 Million | $42.59 Million | ▼ -76.6% |
| 2020 | 1.30x | $22.74 Million | $10.00 Million | $17.53 Million | ▲ +406.1% |
| 2019 | -0.42x | $-8.61 Million | $-9.21 Million | $20.31 Million | — |